Hope
Journal Title: OncoReview - Year 2013, Vol 3, Issue 2
Abstract
In our next article we would like to draw your attention to issue of hope. Taking into account our experience with one of our patient our goal is to establish what hope means for a person in the terminal phase of cancer. Is this is a hope for cure or rather just for another day? A day spent with family or like in the case of our patient hope to remain in control over her life with sense of autonomy and dignity?
Authors and Affiliations
Anna Walaszkowska-Czyż, Małgorzata Kuc-Rajca
Keywords
Related Articles
- EP ID EP53221
- DOI -
- Views 211
- Downloads 0
Toxicity profile of lapatinib plus capecitabine in advanced breast cancer – a single-centre follow-up study
Breast cancer is the most prevalent female neoplasm in Poland as well as in the rest of the world, accounting for 25% of all cancers. Lapatinib is a reversible inhibitor of the HE -1 and HER-2 tyrosine kinase receptors....
Tyrosine kinase inhibitors – should we worry about cardiovascular complications?
Small-molecular tyrosine kinase inhibitors constitute an effective therapeutic option in patients with hematologic malignancies and solid tumours. On the other hand, the significance of cardiovascular adverse events asso...
Carcinosarcoma of the uteri as a third diagnosed malignancy - case report and the review of treatment modality
Progress in metastatic renal cell carcinoma treatment is generally based on new registered drugs. This brings improvement of results but it also needs the choice of proper drug. The decision is especially important in in...
Improving cancer outcomes through better cancer data in Poland
Based on NFZ published aggregate data, the public spending on cancer care in Poland was 6.3 billion PLN in 2011 (or approximately 10% of total public health spending). Poland is one of the few large countries in the worl...
The effect of lipegfilgrastim on hematopoietic reconstitution and supportive treatment after megachemotherapy with autologous peripheral blood stem cell transplantation in patients with lymphoproliferative malignancies
Megachemotherapy with autologous peripheral blood stem cell transplantation (auto-PBSCT) is a standard treatment option in patients below 70 years of age with multiple myeloma (MM) as well as with relapsed and refractory...